Dragonfly Therapeutics Revenue and Competitors

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Dragonfly Therapeutics's estimated annual revenue is currently $20.5M per year.(i)
  • Dragonfly Therapeutics received $Undisclosed in venture funding in May 2017.
  • Dragonfly Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Dragonfly Therapeutics has 132 Employees.(i)
  • Dragonfly Therapeutics grew their employee count by -14% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Dragonfly Therapeutics is a discovery-stage company developing drugs to stimulate immune responses against cancer. We are developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system. These therapies are designed to counterbalance immune suppressive factors present in the tumor microenvironment and mobilize anti-cancer immune responses. Our molecules are expected to be potent as single agents as well as in treatment combinations with existing cancer immunotherapies. Our scientific founders are major figures in cancer biology and immunology and have launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients. For more information, email info@dragonflytx.com.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Dragonfly Therapeutics News

2022-04-13 - Dragonfly Therapeutics Expands Research Collaboration with ...

Will discover and develop Dragonfly's novel immunotherapies for new targets in autoimmune and fibrotic diseases. Dragonfly Therapeutics...

2022-04-13 - Dragonfly Therapeutics Expands Collaboration With AbbVie To Develop Novel Immunotherapies

(RTTNews) - Biotechnology company Dragonfly Therapeutics, Inc. announced Wednesday an expansion of its existing collaboration in oncology...

2022-03-22 - Dragonfly Therapeutics Expands Clinical Leadership Team ...

Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use...

2021-01-12 - Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate USA - English España - español France - Français Deutschland - Deutsch

Dragonfly to receive payment for the first Opt-In from AbbVie as part of a multi-target collaboration launched just over 1 year ago. WALTHAM, Mass., Jan. 12, 2021 /PRNewswire/ -- Dragonfly Therapeutics ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the in ...

2020-12-01 - Dragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients with Solid Tumors USA - English España - español France - Français Deutschland - Deutsch

Merck executes option to license its first immunotherapy candidate from the companies' 2018 collaboration for solid tumor targets. WALTHAM, Mass., Dec. 1, 2020 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced that Merck, known as MSD outside the United States and Ca ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Dragonfly Therapeutics Funding

DateAmountRoundLead InvestorsReference